FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168049883> ?p ?o ?g. }

• W3168049883 endingPage "e19014" @default.
• W3168049883 startingPage "e19014" @default.
• W3168049883 abstract "e19014 Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) but relapse and graft versus host disease (GVHD) remain the most common challenges. Donor lymphocyte infusion (DLI) is the infusion in which lymphocytes from the original stem cell donor are infused, after the transplant, to augment an anti-tumor response or to ensure that the donor stem cells remain engrafted. In this systematic review and meta-analysis, we focused at outcomes of preemptive DLI in AML and MDS. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (PRISMA) PubMed, CINAHL, Cochrane, and Clinical trials.gov were searched. We included 8 out of 214 articles, excluding duplicates and non-relevant articles. The quality of the included studies was evaluated using NIH quality assessment tool. Proportions along with 95% Confidence Interval (CI) were extracted to compute pooled analysis using the ‘meta’ package by Schwarzer et al. in the R programming language (version 4.16-2) to report the efficacy of preemptive DLI. We pooled the experimental arms results of the included trials using the inverse variance method and logit transformation. Between studies, the variance was calculated using Der Simonian-Laird Estimator. Results: We identified 222 patients who received preemptive DLI. Median age, time since transplant and DLI dose were 48 (32-58) years, 82 (7-160) days and 1.4 million cells/kg respectively. CR and PR were 43% (95%CI 0.14-0.78, I 2 93%, n= 127) and 61% (95%CI 0.40-0.78, I 2 62%, n= 81) respectively. After median follow up of 46 months, non-relapsed mortality (NRM) was 52% (95%CI 0.38-0.65, I 2 49%, n = 121). OS was reported 72% (95%CI 0.62-0.80, I 2 0%, n= 100). Acute and chronic GVHD incidence after DLI was 20% (95% CI 0.13-0.29, I 2 4%, n= 105) and 25% (95% CI 0.08-0.56, I 2 =79%, n=101) respectively (Table). Conclusions: Preemptive DLI significantly improves OS with a low incidence of acute and chronic GVHD. However, NRM was seen in more than half of all the patients and prospective studies are needed to evaluate safety of preemptive DLI. Outcomes with preemptive DLI (n= 222).[Table: see text]" @default.
• W3168049883 created "2021-06-22" @default.
• W3168049883 creator A5000881706 @default.
• W3168049883 creator A5005991606 @default.
• W3168049883 creator A5008400959 @default.
• W3168049883 creator A5020679949 @default.
• W3168049883 creator A5024368189 @default.
• W3168049883 creator A5028841827 @default.
• W3168049883 creator A5032238029 @default.
• W3168049883 creator A5041882264 @default.
• W3168049883 creator A5045980983 @default.
• W3168049883 creator A5060121683 @default.
• W3168049883 creator A5062041384 @default.
• W3168049883 creator A5083215041 @default.
• W3168049883 creator A5088949367 @default.
• W3168049883 creator A5089584574 @default.
• W3168049883 creator A5091688355 @default.
• W3168049883 date "2021-05-20" @default.
• W3168049883 modified "2023-10-16" @default.
• W3168049883 title "Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis." @default.
• W3168049883 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e19014" @default.
• W3168049883 hasPublicationYear "2021" @default.
• W3168049883 type Work @default.
• W3168049883 sameAs 3168049883 @default.
• W3168049883 citedByCount "2" @default.
• W3168049883 countsByYear W31680498832022 @default.
• W3168049883 countsByYear W31680498832023 @default.
• W3168049883 crossrefType "journal-article" @default.
• W3168049883 hasAuthorship W3168049883A5000881706 @default.
• W3168049883 hasAuthorship W3168049883A5005991606 @default.
• W3168049883 hasAuthorship W3168049883A5008400959 @default.
• W3168049883 hasAuthorship W3168049883A5020679949 @default.
• W3168049883 hasAuthorship W3168049883A5024368189 @default.
• W3168049883 hasAuthorship W3168049883A5028841827 @default.
• W3168049883 hasAuthorship W3168049883A5032238029 @default.
• W3168049883 hasAuthorship W3168049883A5041882264 @default.
• W3168049883 hasAuthorship W3168049883A5045980983 @default.
• W3168049883 hasAuthorship W3168049883A5060121683 @default.
• W3168049883 hasAuthorship W3168049883A5062041384 @default.
• W3168049883 hasAuthorship W3168049883A5083215041 @default.
• W3168049883 hasAuthorship W3168049883A5088949367 @default.
• W3168049883 hasAuthorship W3168049883A5089584574 @default.
• W3168049883 hasAuthorship W3168049883A5091688355 @default.
• W3168049883 hasConcept C126322002 @default.
• W3168049883 hasConcept C143998085 @default.
• W3168049883 hasConcept C2777408962 @default.
• W3168049883 hasConcept C2778729363 @default.
• W3168049883 hasConcept C2779695342 @default.
• W3168049883 hasConcept C2780007613 @default.
• W3168049883 hasConcept C2780817109 @default.
• W3168049883 hasConcept C2911091166 @default.
• W3168049883 hasConcept C71924100 @default.
• W3168049883 hasConcept C95190672 @default.
• W3168049883 hasConceptScore W3168049883C126322002 @default.
• W3168049883 hasConceptScore W3168049883C143998085 @default.
• W3168049883 hasConceptScore W3168049883C2777408962 @default.
• W3168049883 hasConceptScore W3168049883C2778729363 @default.
• W3168049883 hasConceptScore W3168049883C2779695342 @default.
• W3168049883 hasConceptScore W3168049883C2780007613 @default.
• W3168049883 hasConceptScore W3168049883C2780817109 @default.
• W3168049883 hasConceptScore W3168049883C2911091166 @default.
• W3168049883 hasConceptScore W3168049883C71924100 @default.
• W3168049883 hasConceptScore W3168049883C95190672 @default.
• W3168049883 hasIssue "15_suppl" @default.
• W3168049883 hasLocation W31680498831 @default.
• W3168049883 hasOpenAccess W3168049883 @default.
• W3168049883 hasPrimaryLocation W31680498831 @default.
• W3168049883 hasRelatedWork W1569582079 @default.
• W3168049883 hasRelatedWork W1971561994 @default.
• W3168049883 hasRelatedWork W1999431876 @default.
• W3168049883 hasRelatedWork W2059192060 @default.
• W3168049883 hasRelatedWork W2077564760 @default.
• W3168049883 hasRelatedWork W2078310345 @default.
• W3168049883 hasRelatedWork W2079806356 @default.
• W3168049883 hasRelatedWork W2335567112 @default.
• W3168049883 hasRelatedWork W3031073980 @default.
• W3168049883 hasRelatedWork W3190370440 @default.
• W3168049883 hasVolume "39" @default.
• W3168049883 isParatext "false" @default.
• W3168049883 isRetracted "false" @default.
• W3168049883 magId "3168049883" @default.
• W3168049883 workType "article" @default.